… for molnupiravir treatment included the following: (1) those aged ≥60 years; (2) those aged
≥18 years and are immunocompromised … , most of the participants in the PANORAMIC trial …

… Molnupiravir initially emerged as a possible treatment of … lower in participants receiving 800
mg twice daily molnupiravir … of the following conditions: human immunodeficiency virus (HIV), …

… treatment regimens.A real-world study with hospitalization and death as endpoints demonstrated
that participants receiving three antiviral drugs, Molnupiravir, … to untreated participants. …

… Severe COVID-19 is associated with fatality in older patients, immunocompromised individuals,
and … The safety and efficacy between molnupiravir and placebo-treated participants were …

… Moreover, all our study participants presented with typical SARS-CoV-2 infection … treatment
option but was eventually switched to nirmatrelvir/ritonavir in four patients and to molnupiravir …

… The 2 positive molnupiravir trials included participants primarily with the Delta variant, …
that these treatments may be beneficial to patients who are immunocompromised or have …

… participants were randomized to receive molnupiravir plus usual care or usual care alone
demonstrated that molnupiravir … deterioration despite molnupiravir treatment and developed …

… In the MOVe-OUT trial, 228 participants (15.9%) had diabetes (107 in molnupiravir group
and 121 in placebo group). In the diabetes subgroup, the absolute risk difference in the …

… control, were constructed with inverse probability treatment … women, older adults, and
immunosuppressed individuals(14), … , as participants were censored at first event of interest. …

… RNA from molnupiravir treated participants at Day 3 or Day 5 compared to participants given
… for SARS-CoV-2 in an immunocompromised patient treated with remdesivir 12 . In our study…